SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech News

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Doc Bones5/2/2007 3:16:45 AM
   of 7143
 
Heart-Attack Death Rates Drop
As Treatment Options Improve

Associated Press
May 1, 2007 4:00 p.m.

CHICAGO -- In just six years, death rates and heart failure in hospitalized heart attack patients have fallen sharply, most likely because of better treatment, the largest international study of its kind suggests.

The promising trend parallels the growing use of cholesterol-lowering drugs, powerful blood thinners, and angioplasty, the procedure that opens clogged arteries, the researchers said.

"These results are really dramatic, because, in fact, they're the first time anybody has demonstrated a reduction in the development of new heart failure," said lead author Keith Fox, a cardiology professor at the University of Edinburgh.

The six-year study involved nearly 45,000 patients in 14 countries who had major heart attacks or dangerous partial artery blockages. The percentage of patients who died in the hospital or who developed heart failure was nearly cut in half from 1999 to 2005.

And the heart-attack patients treated most recently were far less likely to have another attack within six months of being hospitalized when compared to the patients treated six years earlier -- a sign that the more aggressive efforts of doctors in the last few years are working.

There have been other signs that better treatment of heart patients has been saving lives, but not on a scale as large as this international study, the researchers said. "It's much more dramatic than we expected, in the course of six years," Dr. Fox said.

The new study follows landmark research results in March that showed angioplasty is being overused on people who have chest pain but are not in immediate danger of a heart attack. But this popular procedure, which typically uses stents to keep an unclogged vessel open, is still a powerful tool for saving those who are having a heart attack or are at high risk of one.

Patients for the study enrolled between July 1999 through December 2005 and were followed for up to six months after hospitalization. Besides the U.S., they were in hospitals in Argentina, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Italy, New Zealand, Poland, Spain and the United Kingdom.

The research showed that in 2005, 4.6% of the heart attack patients died in the hospital, compared with 8.4% in 1999. Heart failure developed in 11% of heart attack patients in 2005, versus nearly 20% in 1999. And just 2% had subsequent heart attacks in 2005, compared to 4.8% previously. Improved outcomes also were found in those with partial blockages, which include less-severe heart attacks.

The researchers said these marked improvements are probably a "direct consequence" of new practices that followed updated guidelines from key organizations of heart doctors in the U.S. and Europe.

The study "is the first report of what's actually going on in the real world," said Joel Gore, a co-author and cardiologist at the University of Massachusetts Medical Center.

Recommendations in those guidelines include quick use of aspirin or more potent blood thinners; beta blockers to reduce the damaged heart's oxygen needs, statins to lower cholesterol; ACE inhibitors to relax blood vessels; and angioplasty to open blocked vessels soon after hospital arrival.

Use of each of these treatments climbed during the study and in some cases more than doubled. For example, 85% of heart patients studied got cholesterol drugs in 2005 versus just 37% in 1999; 78% got potent blood thinners including Bristol-Myers Squibb Co. and Sanofi-Aventis's Plavix versus 30% in 1999; and 53% had quick angioplasty, compared to just 16% six years earlier.

The study appears in Wednesday's Journal of the American Medical Association. It was funded by a grant from Sanofi, which makes several other heart drugs as well as ACE inhibitors. Dr. Fox and several other authors reported getting fees and grants from Sanofi and other drug makers.

Steven Nissen, former president of the American College of Cardiology and a Cleveland Clinic heart specialist, said the study doesn't prove the recommended treatments were saving lives but he suspects that is the case. "I really am encouraged that those things that appear in our guidelines are being used by physicians around the world," Dr. Nissen said.

American Heart Association spokesman Sidney Smith said the results are "exactly what we would hope would happen from the major efforts in this area over the past decade.

"The tragedy is that too many patients delay before coming to the hospital," Dr. Smith said.

online.wsj.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext